AcquiringCerebras Equity
A guide for qualified investors seeking pre-IPO exposure to the leading challenger to NVIDIA's AI chip dominance — building the world's largest processors for AI training and inference at unprecedented scale.
IPO Context: Cerebras originally filed its S-1 in September 2024 but withdrew in October 2025 due to a CFIUS review of its relationship with G42 (Abu Dhabi). CFIUS clearance was received March 2025. The company raised $1B at $23B valuation (Series H, February 2026) as bridge capital and is widely expected to refile and IPO in Q2 2026. This may be the most imminent IPO in this guide series. Data as of March 2026.
Why Cerebras
Cerebras builds the world's largest AI processors — entire silicon wafers turned into single chips. In a market dominated by NVIDIA, Cerebras offers a fundamentally different architecture that eliminates the multi-GPU networking bottleneck. Revenue grew 162% in 2024, though with extreme customer concentration.
Wafer-Scale Engine 3
The WSE-3 is the world's largest processor: 4 trillion transistors, 900,000 AI-optimized cores, on a single silicon wafer. It delivers 7,000x the memory bandwidth of NVIDIA's flagship HBM3e systems, eliminating the inter-GPU communication bottleneck that limits traditional multi-GPU clusters.
4T transistorsAI Inference Speed
Cerebras Inference delivers dramatically faster token generation than GPU-based alternatives. The architecture's on-chip memory eliminates the memory wall problem. Key for enterprises deploying large language models at scale where latency matters — healthcare, finance, real-time applications.
Fastest inferenceMarket Opportunity
The AI accelerator market is projected to exceed $200B by 2028. NVIDIA commands ~80% market share. Even capturing a small percentage represents massive revenue potential. Cerebras is one of very few companies with shipping hardware that offers a genuine architectural alternative to NVIDIA GPUs.
$200B+ TAMCritical Risk — Customer Concentration: G42 (Group 42), an Abu Dhabi-based AI company, accounted for 83% of Cerebras' 2023 revenue and an estimated 97% of hardware sold in H1 2024. This extreme concentration in a single customer — which itself was subject to CFIUS review — is the dominant risk factor. Any disruption in the G42 relationship would be catastrophic to near-term revenue. This has been flagged by analysts as the single biggest concern for IPO investors.
Understanding Private Shares
Cerebras remains private as of March 2026. With an IPO potentially weeks away, the secondary market window is narrow.
Post-IPO (expected)
- Free trading on exchange (likely NASDAQ)
- Full S-1 transparency with audited financials
- Real-time pricing and instant liquidity
- No minimum beyond share price
- No ROFR or transfer restrictions
Where Cerebras Trades Today
- Limited secondary market activity
- Accredited investors only
- Company approval required for transfers
- Minimums typically $25K – $100K+
- IPO may be weeks away — very narrow window
- Prior S-1 filing provides some financial visibility
Unique Advantage — Prior S-1 Filing: Unlike most pre-IPO companies, Cerebras filed an S-1 in September 2024 before withdrawing. This means investors have access to audited financial data through H1 2024 (revenue of $136.4M in that period). While this data is now 18+ months old, it provides significantly more visibility than typical private companies. The refiled S-1 will update these figures.
Accredited Investor Requirements
SEC Rule 501 of Regulation D. At least one criterion required.
Individual income exceeding $200,000
In each of the two most recent years, with reasonable expectation of the same.
Joint income exceeding $300,000
Combined with spouse/spousal equivalent in each of the prior two years.
Net worth exceeding $1,000,000
Excluding primary residence.
FINRA Series 7, 65, or 82 license
Professional certifications qualify regardless of income/net worth.
Qualifying entity or trust
Entities with $5M+ in assets or all equity owners individually accredited.
Select qualifying criteria above
At least one required for private securities transactions.
How to Buy
Given the imminence of the IPO, secondary market access may be limited. Consider whether waiting for the public listing is the better path.
Secondary Market Platforms
Cerebras shares have appeared on secondary platforms, though availability is more limited than mega-cap names like SpaceX or Databricks. The narrow IPO window means inventory may dry up as insiders hold for the public listing.
SPVs
Some SPV managers have assembled Cerebras positions. Given the imminent IPO, new SPV formation may be limited. Existing SPVs may still accept investors.
Wait for the IPO
With an IPO potentially in Q2 2026, waiting is a legitimate strategy. You gain: audited S-1 financials, immediate liquidity, no ROFR, transparent pricing, and the ability to size your position precisely. You lose: potential IPO pop upside if shares are priced conservatively. For Cerebras specifically, this may be the most rational path given how close the IPO is.
Step-by-Step Process
If pursuing pre-IPO purchase. Total time: 3–6 weeks — but the IPO may arrive within this window.
Verify Accredited Status
Standard verification through platform or third-party service.
1 – 5 business daysLocate Available Shares
Check Forge, Hiive, EquityZen for Cerebras inventory. Supply may be very limited given IPO proximity. Insiders are likely holding for the public listing.
Varies — may not be availableEvaluate Pricing vs. Expected IPO
Compare secondary market price against the $23B Series H valuation and any leaked IPO pricing signals. The original S-1 targeted an ~$8B IPO; the current $23B private valuation represents nearly 3x that. Ensure you're not paying a premium that the public market won't support.
Critical analysis stepExecute & Fund
Sign purchase agreement, fund escrow. Standard SPA review by your attorney.
3 – 7 business daysCompany Approval Period
Board approval and ROFR window. With IPO imminent, company may be more or less permissive — unpredictable.
15 – 30 business daysSettlement
If approved before IPO: shares transfer on cap table. If IPO occurs during settlement: the transaction may be complicated. Discuss IPO-contingency clauses with your attorney. Pre-IPO shares will be subject to 90–180 day post-IPO lock-up.
5 – 10 business daysKey Considerations
Cerebras carries unique risks that differ substantially from enterprise software companies. Customer concentration and NVIDIA dominance are the defining challenges.
Customer Concentration
G42 accounted for 83% of 2023 revenue and ~97% of H1 2024 hardware sales. This is an extreme, single-customer dependency. If G42 reduces orders, delays payments, or faces its own regulatory issues, Cerebras' revenue could collapse. The S-1 will show whether diversification has improved, but this remains the #1 risk.
G42 = 83-97% of revenueNVIDIA Dominance
NVIDIA holds ~80% of the AI accelerator market with a massive software ecosystem (CUDA). Most AI frameworks are optimized for NVIDIA GPUs. Switching costs are high. Cerebras must prove its wafer-scale architecture is worth the ecosystem migration. NVIDIA's roadmap (Blackwell, Rubin) is relentless.
NVIDIA ~80% market shareExport Control Risk
U.S. chip export restrictions to China and the Middle East directly affect Cerebras. The UAE (G42's home market) falls into restricted export control country groups. The prior CFIUS review (resolved March 2025) centered on G42's potential role in funneling AI technology to restricted regions. Future regulatory tightening could limit Cerebras' addressable market.
CFIUS + export controlsSingle-Product Risk
Cerebras' entire business is built on the Wafer-Scale Engine. If the architecture hits scaling limits, manufacturing yield issues, or fails to keep pace with NVIDIA's improvements, there is no diversified product portfolio to fall back on. Compare to NVIDIA's data center, gaming, automotive, and professional visualization segments.
One product lineIPO Timing Risk
The IPO is expected in Q2 2026 but has already been delayed once (original S-1 filed Sept 2024, withdrawn Oct 2025). Further delays are possible if market conditions deteriorate, if the refiled S-1 draws SEC comments, or if new regulatory issues emerge. Pre-IPO buyers must be prepared for the possibility of extended illiquidity.
Already delayed onceBuy Now vs. Wait
With the IPO potentially weeks away, waiting is a strong option. Post-IPO: full audited financials, instant liquidity, no ROFR, transparent pricing. Pre-IPO: potential discount to IPO price, but also ROFR risk, illiquidity, and the chance that the IPO arrives before your transaction settles. For most investors, waiting for this specific company is likely the more rational path.
Waiting may be wisestValuation Trajectory
Original S-1 targeted ~$8B IPO valuation. Series H (Feb 2026) valued at $23B — nearly 3x the original IPO target. If the public market disagrees with this re-rating, IPO-day pricing could be below the latest private round. Cerebras must demonstrate significant revenue growth and customer diversification to justify the jump.
$8B → $23B in 16 monthsTax Considerations
At $23B valuation, Cerebras does not qualify for QSBS (Section 1202) — assets exceed the $75M threshold. Standard capital gains treatment applies. Note: if you purchase pre-IPO and the IPO occurs shortly after, your holding period starts from your purchase date, not the IPO date. Plan accordingly for short-term vs. long-term capital gains implications.
No QSBS